Oxurion N.V. (OXUR.BR)
Oxurion N.V. operates in the Biotechnology industry of the Healthcare sector, headquartered in Leuven, VL, BE. The stock last traded at $0.00, up 0.00% on the session, giving a market capitalisation of $365,910. Its beta of -0.11 implies it has historically moved less than the broad market.
Headquartered in Leuven, Belgium, and established in 1991, Oxurion N.V. is a biopharmaceutical firm focused on researching, developing, and bringing to market treatments for various ocular conditions worldwide. Its primary commercialized offering is JETREA, a medication used to address vitreomacular adhesion and vitreomacular traction. The company's development pipeline includes THR-149, a plasma kallikrein inhibitor currently undergoing Phase II clinical trials for diabetic macular edema (DME), and THR-687, an integrin antagonist also in Phase II trials for DME. Oxurion has forged strategic partnerships with Bicycle Therapeutics, INC Research, and Galapagos NV. The organization was formerly known as ThromboGenics NV before officially changing its name to Oxurion NV in September 2018.
Oxurion N.V. is most often compared with the following Healthcare names: